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Microparticles are plasma membrane vesicles with procoagulant and
proinflammatory properties. We recently demonstrated that microparticles induce
vascular hyporeactivity and evoke up-regulation of proinflammatory protein
expression. This study dissected the effect of either in vitro treatment or short-term
oral administration of the peroxisome proliferator-activated receptor-γ (PPARγ)
agonist, rosiglitazone, on microparticle-induced vascular hyporeactivity of mouse
vessels. Microparticles were produced from T cells by actinomycin D treatment. The
effects of rosiglitazone on mouse aortic rings incubated with microparticles were
investigated. Aortae treated in vitro with rosiglitazone or aortae taken from mice
treated by oral administration of the same agonist completely prevented
microparticle-induced vascular hyporeactivity in response to U46619 [9,11-
dideoxy-11α, 9α-epoxymethanoprostaglandin F2α). These effects of rosiglitazone
occurred independently of the presence of endothelium without modifications in
blood parameters. The mechanisms involved abrogation of nitric oxide (NO) and
prostacyclin overproduction linked to up-regulation of inducible NO-synthase and
cyclooxygenase 2 elicited by microparticles. In addition, rosiglitazone treatment
reduced the ability of microparticles to evoke increases in interleukin (IL)-6, IL-8,
and nuclear factor (NF)-κB transcription, and NF-κB expression and activation.
These results suggest that rosiglitazone, via PPARγ activation, counteracts vascular
dysfunction associated with increased release of proinflammatory proteins elicited
by microparticles. They underscore therapeutic perspective for rosiglitazone in
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